Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS5917779B2 - Method for producing specific antibody against HBsAg - Google Patents
[go: Go Back, main page]

JPS5917779B2 - Method for producing specific antibody against HBsAg - Google Patents

Method for producing specific antibody against HBsAg

Info

Publication number
JPS5917779B2
JPS5917779B2 JP8881976A JP8881976A JPS5917779B2 JP S5917779 B2 JPS5917779 B2 JP S5917779B2 JP 8881976 A JP8881976 A JP 8881976A JP 8881976 A JP8881976 A JP 8881976A JP S5917779 B2 JPS5917779 B2 JP S5917779B2
Authority
JP
Japan
Prior art keywords
fraction
slow
immunoglobulin
specific antibody
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP8881976A
Other languages
Japanese (ja)
Other versions
JPS5315415A (en
Inventor
八尋 上村
俊彦 田中
哲 船越
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GC Biopharma Corp
Original Assignee
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Korea filed Critical Green Cross Corp Korea
Priority to JP8881976A priority Critical patent/JPS5917779B2/en
Publication of JPS5315415A publication Critical patent/JPS5315415A/en
Publication of JPS5917779B2 publication Critical patent/JPS5917779B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

【発明の詳細な説明】 本発明はHB、Agに対する特異抗体の製造方法に関す
る。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing specific antibodies against HB and Ag.

更に詳しくは、血漿又は血清の免疫グロブリンIgG、
又はこれらを分画して得られる精製グロブリンから、B
型肝炎に関係してい■)HB、Agに対する特異抗体(
以下抗HB。
More specifically, plasma or serum immunoglobulin IgG,
Or from purified globulin obtained by fractionating these, B
Related to type hepatitis ■) Specific antibodies against HB and Ag (
Anti-HB below.

と記す)が集中していることを新規に見いだした電気泳
動的に「スロウ(s10w)」の免疫グロブリン画分を
、既知の分画技術に工つて選択的に取得することに関す
るものである。HBsAgはヒト血清中などに存在し、
いわゆる輸血肝炎ウィルスないし同ウィルスに密接な関
係を持つ物質と考えられ、輸血肝炎の予防対策上、輸血
すべき血液のHBsAgの有無を検出することは、現に
広く行われている重要な臨床検査法である。
This invention relates to the selective acquisition of an electrophoretically slow (s10w) immunoglobulin fraction, which has been newly discovered to be concentrated in electrophoretically (denoted as s10w), using known fractionation techniques. HBsAg exists in human serum, etc.
It is considered to be the so-called transfusion hepatitis virus or a substance closely related to the same virus, and as a preventive measure against transfusion hepatitis, detecting the presence or absence of HBsAg in the blood to be transfused is an important clinical test method that is currently widely used. It is.

従来、血清中のHBAは抗HB血清を用いるウクテルロ
ニー(Ouchterlony)法、カウ5 ンター
・エレクトロフオレーシス( Counter一ele
ctrophoresis)、補体結合反応、感性血球
凝集阻止反応などで判定されて来た。
Conventionally, HBA in serum has been determined using the Ouchterlony method using anti-HB serum, countermeasures, etc.
・Electrophoresis (Counter-ele)
ctrophoresis), complement fixation reaction, sensitive hemagglutination inhibition reaction, etc.

しかしながら、これらの従来法は判定に長時間を要し、
手技も煩雑であつた。最近、抗HBグロブリンを吸、1
0着させたラテックスを検査すべき血清に混合し、数分
間軽く振盪することによつてHBAを含む血清において
は、ラテックスの凝集が起き、HB。
However, these conventional methods require a long time to make a determination;
The procedure was also complicated. Recently, I took anti-HB globulin and
By mixing the coated latex with the serum to be tested and gently shaking it for several minutes, agglutination of the latex occurs in the serum containing HBA, resulting in HB.

へを含まない血清では起きないので、両者の区別が可能
であるとの報告があり、その原理によつて作15製した
HBsAg検出試薬が市販されている。しかし、この試
薬にも次のような欠点があり、少なくとも前記の諸検査
法に代りるものではないと考えられ7■)。1他の方法
よりも特に鋭敏ではなく、他の方法で明らかにHBAを
含むと判定される血20清でも、しばしば陰性と判定さ
れ■)02原因不明の非特異的凝集反応によつてHBA
を含まないヒト血清が陽性と判定されることがあろ。
It has been reported that HBsAg detection does not occur in serum that does not contain HBsAg, so it is possible to distinguish between the two, and a reagent for detecting HBsAg prepared based on this principle is commercially available. However, this reagent also has the following drawbacks, and it is considered that it cannot at least replace the various testing methods described above7). 1 It is not particularly sensitive than other methods, and even serum that is clearly determined to contain HBA20 by other methods is often determined to be negative.
Human serum that does not contain this substance may be determined to be positive.

このように、簡便迅速、かつ正確にHBAを検出しうる
検出方法はいまだ存在せず、したがつ25てこのような
HB、Ag検出方法並びに検出剤の確立が要望されてい
た。
As described above, there is still no detection method that can simply, quickly, and accurately detect HBA, and there has been a desire to establish such a method and a detection agent for detecting HB and Ag.

本発明者らは、このような技術的背景の下に、濃度の高
い抗HBグロブリンの取得方法を検討し、その結果、目
的とする特異抗体、抗HB、を得、これを粒状担体に感
性さ30せて得られる試薬は、従来にない非特異的凝集
の少ない逆受身担体凝集反応用HB、Ag検出試薬であ
ることを見いだした。
Based on this technical background, the present inventors investigated a method for obtaining high-concentration anti-HB globulin, and as a result, obtained the target specific antibody, anti-HB, and sensitized it to a granular carrier. It has been found that the reagent obtained in this manner is an HB and Ag detection reagent for reverse passive carrier agglutination reactions with less nonspecific aggregation than ever before.

本発明は、抗HBs陽性の血漿又は血清ユリ得られる免
疫グロブリンから、電気泳動的にγ位35(特に好まし
くは、ユリ塩基性の高いγ位)に属するスロウエ8G金
分取することを特徴とするHBsAgに対する特異抗体
(抗HB。
The present invention is characterized in that Slowe 8G gold belonging to the γ-position 35 (particularly preferably the highly basic γ-position) is fractionated electrophoretically from immunoglobulin obtained from anti-HBs-positive plasma or serum. A specific antibody against HBsAg (anti-HB).

)の取得方法を提供するものである。).

一般に免疫グロブリンIGは電気泳動的に主としてγ位
に属するとはg〜・え、一部はα位にまで及んでおり、
α,β位に属するものは「フアーストIG(FastI
G)」、Ggγ位に属するものは「スロウIgG(Sl
OwlgG)」、と呼ばれている。
In general, immunoglobulin IG electrophoretically belongs mainly to the γ position, but some extend to the α position.
Those belonging to the α and β positions are “Fast IG”
G)", those belonging to the Ggγ position are "slow IgG (Sl
OwlgG)".

例えば、本発明者らの知見によれば、破傷風抗体はスロ
ウIGの中でも、最も塩基性部分に抗g体価の高いこと
を見いだしている(第23回輸血学会発表)。
For example, according to the findings of the present inventors, it has been found that the tetanus antibody has the highest anti-g titer in the basic part of slow IG (Presentation at the 23rd Society of Blood Transfusion).

このように、抗体は電気泳動的に見た場合でも、その種
類によつて特異的に局在しており、フアーストIGに抗
体活性の集中するものもあるGO 一方抗HBに関しては現在までその活性の電S気泳動的
な分布は不明であり、特に抗原抗体反応における特異性
という観点からの分布は全く不明であつた。
In this way, even when viewed electrophoretically, antibodies are localized specifically depending on their type, and some antibodies have antibody activity concentrated in Fast IG. The electrophoretic distribution of this substance was unknown, and in particular, the distribution from the viewpoint of specificity in antigen-antibody reactions was completely unknown.

発明者らは、この事を解決すべく、高度免疫抗HB,/
陽性のヒト血漿を用いて、研究を重ね、抗HBがスロウ
IGに局在しており、特に電8g気泳動的に塩基性の高
いγ位に集中していることを初めて見いだした。
In order to solve this problem, the inventors developed hyperimmune anti-HBs,
Through repeated research using positive human plasma, it was discovered for the first time that anti-HB was localized in slow IG, and was particularly concentrated at the γ position, which is electrophoretically highly basic.

更にこの抗体画分を粒状担体に感作して、抗原一抗体反
応による抗体の凝集反応を行う時、従来の方法で得た抗
体を感作したものに比べ、極めて特異性の高い反応を示
すことを見いだした。免疫グロブリンは周知のように血
漿又は血清を出発物として、エタノール分画法、硫安分
画法、リバノール分画法、イオン交換クロマトグラフイ
一法、又は等電点分画法、更にはこれらの方法の組合せ
によつて得られ7)。
Furthermore, when a particulate carrier is sensitized with this antibody fraction and an antibody agglutination reaction is performed through an antigen-antibody reaction, the reaction is extremely highly specific compared to sensitization with antibodies obtained by conventional methods. I found out. As is well known, immunoglobulin can be produced using plasma or serum as a starting material, using ethanol fractionation, ammonium sulfate fractionation, ribanol fractionation, ion exchange chromatography, or isoelectric focusing, as well as these methods. obtained by a combination of methods 7).

一般に免疫グロブリンは電気泳動に対する挙動を異にす
る画分に区別され、易勤度に工つて、α2,β1,β2
,γ1,γ2などの画分が知られている。
In general, immunoglobulins are divided into fractions with different electrophoretic behavior.
, γ1, γ2, and other fractions are known.

これらのα位、β位及びγ位、それぞれの分画法として
は陽イオン交換クロマトグラフイ一法〔イムノケミスト
リ一(ImmunOchemistry:A,lOl(
1967)〕、陰イオン交換クロマトグラフイ一法〔ト
ランスフユージヨン(TransfussiOn]6,
146(1966)〕及びプロツク電気泳動法〔電気泳
動実験法、p、303、電気泳動学会編(文光堂)〕等
電点分画法〔生物物理化学14(3)21,209,(
1969)〕などが公知である。本発明においては、ヒ
トの抗HB陽性の血漿)
S又は血清から常法に従つて得られた免疫グロブリ
ンを、公知の方法に工つて分画し、γ一位(γ1,γ2
)画分、好ましくはγ2からなる塩基性のより大きい画
分を得るのである。
As a fractionation method for each of these α-, β-, and γ-positions, cation exchange chromatography (ImmunOchemistry: A, 1Ol) is used.
1967)], Anion Exchange Chromatography Method [TransfussiOn] 6,
146 (1966)] and Prock electrophoresis method [Electrophoresis Experimental Methods, p. 303, edited by the Electrophoresis Society (Bunkodo)] and isoelectric focusing method [Biophysical Chemistry 14 (3) 21, 209, (
1969)] are publicly known. In the present invention, human anti-HB positive plasma)
Immunoglobulin obtained from S or serum according to a conventional method is fractionated using a known method, and the γ1 position (γ1, γ2
) fraction, preferably a more basic fraction consisting of γ2.

前記の公知の分画法のうち、用いる試薬、操作及び条件
において最も好ましい分画法はイオン交換クロマトグラ
フイ一法である。
Among the above-mentioned known fractionation methods, the most preferred fractionation method in terms of the reagents, operations, and conditions used is ion exchange chromatography.

しかし、免疫吸着法も、必要とされる高度に精製された
HBAlSgを用いること及び製品の多少の特異性並び
に抗体価の減弱を予期するならば、用いることができる
However, immunoadsorption methods can also be used, provided one uses the highly purified HBAlSg required and anticipates some specificity of the product and attenuation of the antibody titer.

イオン交換クロマトグラフィー法による分画の条件は、
各担体によつて選択的であるけれども、いずれにせ工、
分画され友フラクシヨンの中から抗HBの集中した電気
泳動的にスロウIGにSg局在する画分を、分取すれば
工いのである。
The conditions for fractionation by ion exchange chromatography are as follows:
In any case, although selective for each carrier,
This can be done by separating the fraction in which anti-HB is concentrated and Sg is electrophoretically localized in slow IG from the fractionated fraction.

例えば、陽イオン交換体を用い友時には0.2〜0.0
05M.H4〜7のリン酸緩衝液で平衡化し友担体゛p
に免疫グロブリンを吸着させ、塩濃度を上げながら免疫
グロブリンを溶出させる。
For example, when using a cation exchanger, 0.2 to 0.0
05M. Equilibrate with H4-7 phosphate buffer and transfer
Immunoglobulin is adsorbed to the solution, and the immunoglobulin is eluted while increasing the salt concentration.

溶出液の中から、上記の目的とする抗体を含む画分を吟
味し、分取する。又、陰イオン交換体を用いる時は、0
.1〜0.005M,H7〜10のリン酸緩衝液で担体
をp平衡化して、免疫グロブリンを吸着、塩濃度を上げ
つつ分別溶出させる。
From the eluate, the fraction containing the above-mentioned target antibody is examined and separated. Also, when using an anion exchanger, 0
.. The carrier is p-equilibrated with a phosphate buffer of 1 to 0.005 M, H7 to 10, and immunoglobulin is adsorbed and fractionated and eluted while increasing the salt concentration.

かくしてγ−グロブリンのスロウ画分が得られる。以下
に、本発明を実施例によつて更に具体的に説明する。
In this way, a slow fraction of γ-globulin is obtained. EXAMPLES Below, the present invention will be explained in more detail with reference to Examples.

実施例 抗HB陽性のヒト血漿11から出発して、コSーンのエ
タノール分画法に従つて、粗製免疫グロブリン画分8.
29を得た。
Example Starting from anti-HB positive human plasma 11, crude immunoglobulin fractions 8.
I got 29.

このもののPHA法(受身赤血球凝集反応法)での抗H
B8の抗体価は、1(:fl)溶液で測定する時、1:
8000であつた。次にこの免疫グロブリン19を0.
01Mリン酸緩衝液(H6.O)に対して1夜透析後、
同じ緩p衝液で平衡化し友CM−セルロース(Serv
a社製)のカラム(径3CTIL長さ30?)に載せて
吸着させ、平衡化に用い友と同じ緩衝液で十分洗浄した
Anti-H by PHA method (passive hemagglutination assay) of this product
The antibody titer of B8 is 1: when measured with a 1(:fl) solution.
It was 8000. Next, this immunoglobulin 19 was added to 0.
After overnight dialysis against 01M phosphate buffer (H6.O),
Equilibrate with the same pH buffer and add CM-cellulose (Serv
It was adsorbed on a column (diameter: 3CTIL, length: 30?) manufactured by Company A), used for equilibration, and thoroughly washed with the same buffer solution as that used for the column.

次に、0.01M,H6.0のリン酸緩衝液と、ゝ
PO.OlM,H6.Oのリン酸緩衝液にNa
CllcpO.4M加えた溶液を用いて濃度勾配溶出を
行つ友。
Next, 0.01M, H6.0 phosphate buffer and
P.O. OlM, H6. Na in phosphate buffer of O
CllcpO. A friend who performs concentration gradient elution using a solution containing 4M.

初期に溶出してくる画分はフアーストIG画g分、後期
に溶出してくるのがスロウI,G画分、その中間がミド
ルIG(MiddleIG)画分としGgて確認され友
It was confirmed that the early eluting fraction is the fast IG fraction, the late eluting fraction is the slow I, G fraction, and the middle one is the middle IG fraction.

それぞれをブールした後、必要に応じて減圧濃縮して、
1%濃度に統一し、PHA法で抗HBの抗体価を測定し
たところ、フア一SストIG画分では1:64にすぎな
いが、スロgウIG画分では1:64000を示し、8
倍にg精製された。
After each boule, concentrate under reduced pressure as necessary.
When we standardized the concentration to 1% and measured the anti-HB antibody titer using the PHA method, it was only 1:64 in the FAST IG fraction, but 1:64,000 in the SLOW IG fraction, and 8%.
Purified by 2 times g.

分取した各画分の1%液を用いて免疫電気泳動を行うと
、抗HB活性の集中したスロウIG) Sg
画分は免疫グロブリンの内でも最も陰極側へ泳動され、
フアーストIG画分は最も陽極側へ泳動)
gされた。
When immunoelectrophoresis was performed using a 1% solution of each fraction, it was found that Slow IG (Sg) with concentrated anti-HB activity
The fraction migrates toward the cathode side among immunoglobulins,
The first IG fraction migrates toward the anode side)
g was given.

ミドルIG画分は両者の中間的位置に0g泳動された。The middle IG fraction was migrated at 0g at a position intermediate between the two.

試験例 実施例のCM−セルロースで分画したスロウIG画分、
フアーストIG画分及び実施例1gSgで示した粗製免
疫グロブリンを出発原料として、アフイニテイクロマト
グラフイ一法〔フオツクスサング(0xSang.)、
29,319,(1975)〕で精製したIgG〔アフ
イニテイI,G(AffinityIG)〕 とを用い
て、その一定量をグルタールアgルテヒド処理した緬羊
赤血球に感作し、得られた試薬の特異性を比較した。
Test Examples Slow IG fraction fractionated with CM-cellulose,
Using the Fast IG fraction and the crude immunoglobulin shown in Example 1gSg as starting materials, an affinity chromatography method [OxSang.
29, 319, (1975)] was used to sensitize sheep red blood cells treated with glutar agluthehyde with a certain amount of IgG [Affinity IG], and the specificity of the obtained reagent was tested. compared.

すなわち緬羊赤血球をリン酸緩衝化生理食塩水で4回洗
浄し、これを5%濃度の懸濁液にする。
That is, sheep red blood cells are washed four times with phosphate buffered saline and made into a 5% suspension.

これにグルタールアルデヒドの2.5%溶液を20%の
割合で加え、室温にて60分間反応を行い、次いで上記
の生理食塩水で4回洗浄して未反応のグルタールアルデ
ヒドを除くと固定化赤血球が得られる。この固定化赤血
球を5%濃度の懸濁液とし、以下今井らの方法(医学の
あゆみ、78,759760(1970))に準じて各
種免疫グロブリンを感作した。
A 2.5% solution of glutaraldehyde was added to this at a ratio of 20%, the reaction was carried out at room temperature for 60 minutes, and then the unreacted glutaraldehyde was removed by washing four times with the above physiological saline and fixed. erythrocytes are obtained. The fixed red blood cells were made into a 5% suspension and sensitized with various immunoglobulins according to the method of Imai et al. (Igaku no Ayumi, 78, 759760 (1970)).

表1は抗体感作赤血球の特異性を調べるために成人血清
2605人について陽性及び精製刊〜を用いた凝集阻止
反応による偽陽性の有無についてまとめたものである。
Table 1 summarizes the presence or absence of positive sera from 2,605 adult sera and the presence or absence of false positives by agglutination inhibition reaction using purified erythrocytes to examine the specificity of antibody-sensitized red blood cells.

フアーストIgG画分で感作したものは偽陽性が707
人と極めて高く、免疫グロブリンの中でもフアーストI
G画分中gにはこの工うな非特異的反応の原因となる成
分が集められていることが分かる。
There were 707 false positives in those sensitized with the first IgG fraction.
It is extremely high in humans, and is the first I among immunoglobulins.
It can be seen that components that cause this unspecific reaction are collected in g in the G fraction.

一方、従来のアフイニテイクロマトグラフイで精製した
IGで感g作したものは、偽陽性が11人であつたが、
スロウIGを用いた場合はこれ工り更に著しく改善gさ
れ、約1/3にまで少なくなつた。
On the other hand, in those sensitized with IG purified by conventional Affinity chromatography, there were 11 false positives;
When slow IG was used, this process was even more significantly improved, and was reduced to about 1/3.

この工うに除去したフアーストIG画分は非g特異反応
が高く、スロウIG画分では非特異反)
g応性が、その約1/57になることから、免疫グロ
ブリンをスロウIG画分と、フアーストIGgSg画分
とに分画する方法の有効性が明らかである。
The fast IG fraction removed in this way has a high non-g-specific reaction, while the slow IG fraction has a high non-specific reaction).
Since the g response is approximately 1/57 of that, the effectiveness of the method of fractionating immunoglobulin into a slow IG fraction and a fast IGgSg fraction is clear.

更に同様に従来技術で高度精製された抗HB画S分も
スロウIGとフアーストIGとに分画ゝ
Ggすることの有効性を示唆するものである。
Furthermore, anti-HB fraction S highly purified using conventional technology
Fractionated into slow IG and fast IG
This suggests the effectiveness of Gg.

Claims (1)

【特許請求の範囲】[Claims] 1 抗HB_s陽性の血漿又は血清より得られる免疫グ
ロブリンから、HB_sA_gに対する特異抗体(抗H
B_s)の取得方法において、電気泳動的に塩基性の高
いγ位に属する「スロウI_gGを分取することを特徴
とする抗HB_sの製造方法。
1. A specific antibody against HB_sA_g (anti-H
A method for producing anti-HB_s, which comprises separating "slow I_gG" belonging to the γ-position, which is electrophoretically more basic.
JP8881976A 1976-07-26 1976-07-26 Method for producing specific antibody against HBsAg Expired JPS5917779B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8881976A JPS5917779B2 (en) 1976-07-26 1976-07-26 Method for producing specific antibody against HBsAg

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8881976A JPS5917779B2 (en) 1976-07-26 1976-07-26 Method for producing specific antibody against HBsAg

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP7767881A Division JPS5716357A (en) 1981-05-22 1981-05-22 Hbsag detecting reagent

Publications (2)

Publication Number Publication Date
JPS5315415A JPS5315415A (en) 1978-02-13
JPS5917779B2 true JPS5917779B2 (en) 1984-04-23

Family

ID=13953517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8881976A Expired JPS5917779B2 (en) 1976-07-26 1976-07-26 Method for producing specific antibody against HBsAg

Country Status (1)

Country Link
JP (1) JPS5917779B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61110894U (en) * 1984-12-24 1986-07-14

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181713A (en) * 1978-10-30 1980-01-01 Merck & Co., Inc. Isolation of HBs Ag
JPS56106769U (en) * 1980-01-18 1981-08-19

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61110894U (en) * 1984-12-24 1986-07-14

Also Published As

Publication number Publication date
JPS5315415A (en) 1978-02-13

Similar Documents

Publication Publication Date Title
Benedict et al. Physical properties of antibody to bovine serum albumin as demonstrated by hemagglutination
Muller-Eberhard et al. Isolation and characterization of two ẞ1-glycoproteins of human serum
Thompson et al. Reactive lysis: the complement-mediated lysis of unsensitized cells: I. The characterization of the indicator factor and its identification as C7
US4145406A (en) Specific binding - adsorbent assay method and test means
US4254082A (en) Specific binding-adsorbent assay test means
Lenkei et al. Methods for detection of anti-albumin autoantibodies in hepatic diseases
US4189464A (en) Hepatitis B testing reagent and method
Lalezari et al. Identification of a specific leukocyte antigen: another presumed example of 5b
Wolff et al. A two‐component system of human serum agglutinating gelatine‐coated erythrocytes
Thurston et al. A rapid method for recovering serologically active globulins by sodium sulfate precipitation
Wilkinson et al. Immunochemical characterization and serologic behavior of antibodies against red cells in infectious mononucleosis
US4132767A (en) Preparation of α-L antibody, purification of α-L antigen and reagent for detection of α-L antibody and α-L antigen
JPS5917779B2 (en) Method for producing specific antibody against HBsAg
Poon et al. Heterogeneity of human circulating anticoagulants against antihemophilic factor (factor VIII)
Wallwork et al. The SIgA system and hypersensitivity in patients with cystic fibrosis
Fäldt et al. Heat production in different populations of human blood cells exposed to immune complexes in vitro: the importance of the Fc parts of immunoglobulins and the influence of active complement
Faulk et al. Characterization of rabbit fast and slow 6· 6S IgG
Wilson et al. Naturally occurring human antibodies to pepsin-digested IgA
JPS6122262B2 (en)
Keir et al. Nitrocellulose immunofixation following agarose electrophoresis in the study of immunoglobulin G subgroups in unconcentrated cerebrospinal fluid
JPS6231301B2 (en)
JPS6215464A (en) Non-specific reaction absorbent for reverse passive agglutination reaction
Moore et al. Purification and use of the C3d subunit of C3
Steward et al. Low molecular weight mercaptoethanol sensitive antibody in rabbits
JPS5848856A (en) Preparation of specific antibody for hbeag and detection reagent of hbeag